Denifanstat

Denifanstat is a first-in-class, orally active fatty acid synthase inhibitor that has garnered significant attention in both oncology and metabolic disease research. As a selective FASN inhibitor with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM, Denifanstat blocks the de novo synthesis of palmitic acid, a critical pathway for tumor cell survival and proliferation. Denifanstat has been studied in clinical trials for the treatment of various cancers, including solid tumors, where FASN overexpression is associated with poor prognosis and drug resistance. Denifanstat also demonstrates potential in the treatment of non-alcoholic steatohepatitis, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis. The compound has shown promising anti-viral activity as well, with reports indicating inhibition of SARS-CoV-2 infection at nanomolar concentrations (EC₅₀ = 4 nM) in ACE2-expressing cells. Denifanstat is supplied as a high-purity research compound, typically ≥95% purity, for preclinical and clinical research applications, with formulations for oral administration in development.

 

 Product Parameters

---

Parameter	Specification
Product Name	Denifanstat
CAS Number	1399177-37-7
Molecular Formula	C₂₇H₂₉N₅O
Molecular Weight	439.55 g/mol
Appearance	White to off-white solid
Boiling Point	708.3±70.0℃
Density	1.27±0.1 g/cm3
Solubility	Soluble in DMSO
pKa	9.96±0.40

 

Bioactivity

---

TVB-2640 (ASC-40, FASN-IN-2) is an orally administered, bioavailable inhibitor of fatty acid synthase (FAS/FASN) with therapeutic potential for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis.

 

Why Cosperpharm?

---

When your oncology or metabolic disease research program requires high-purity Denifanstat with comprehensive analytical documentation and reliable supply, Cosperpharm delivers the quality and support that researchers demand.

 

Purity you can trust for reproducible research. Denifanstat is a potent FASN inhibitor, and batch-to-batch consistency is critical for generating reliable experimental data. Cosperpharm supplies Denifanstat with HPLC purity ≥95%, ensuring that your experimental results are not compromised by impurities or degradation products.

 

Documentation that supports your research. Every shipment of Denifanstat includes a Certificate of Analysis (COA) with batch-specific purity data, appearance verification, and solubility information. Additional analytical data including HPLC chromatograms and mass spectrometry confirmation are available upon request.

 

Flexible supply for all research scales. Cosperpharm supplies Denifanstat across the full range of research applications — from milligram quantities for in vitro screening and cell-based assays, to gram-scale batches for in vivo pharmacokinetic and efficacy studies, to larger quantities for formulation development and toxicology studies.

 

Technical support from experienced chemists. Our scientific team can advise on solubility optimization, formulation strategies, storage conditions, and analytical methods for Denifanstat — because we understand the challenges of working with novel research compounds.

 

Global reach with transparent pricing. Cosperpharm ships to research institutions, pharmaceutical companies, and CROs worldwide, with full customs documentation included. We communicate lead times upfront — no hidden fees, no unexpected delays.

 

 Product Advantages

---

First-in-Class FASN Inhibitor

Denifanstat is a first-in-class, orally active fatty acid synthase inhibitor with potent anti-cancer and metabolic disease therapeutic potential. As one of the most advanced FASN inhibitors in clinical development, Denifanstat represents a novel therapeutic approach targeting tumor metabolism.

 

 High Potency and Selectivity

Denifanstat demonstrates exceptional potency with an IC₅₀ of 0.052 μM and an EC₅₀ of 0.072 μM against FASN. This high potency translates to effective inhibition of de novo fatty acid synthesis at low concentrations, minimizing off-target effects and improving therapeutic index.

 

 Broad Therapeutic Applications

Denifanstat has shown promise across multiple therapeutic areas: oncology (solid tumors, including those with FASN overexpression), metabolic disease (non-alcoholic steatohepatitis), and infectious disease (SARS-CoV-2 inhibition at EC₅₀ = 4 nM). This broad therapeutic potential makes Denifanstat a valuable tool for diverse research programs.

 

 Orally Bioavailable

Denifanstat is orally bioavailable, enabling convenient oral administration in preclinical and clinical studies. This property facilitates chronic dosing regimens and improves translational relevance for human therapeutic applications.

 

 Well-Characterized Research Compound

Denifanstat is supplied with comprehensive characterization data including HPLC purity, mass spectrometry confirmation, and solubility profiles. This rigorous characterization ensures reproducibility across experiments and laboratories.

 

Contact Us

---

Advancing your FASN inhibitor research program requires a reliable partner who understands the importance of compound quality and documentation. Cosperpharm is here to support your research with high-purity Denifanstat, comprehensive analytical data, and responsive customer service. Contact our team today to discuss your requirements.